Literature DB >> 21895625

Misdiagnosis and delay in referral of children with localized scleroderma.

L Weibel1, B Laguda, D Atherton, J I Harper.   

Abstract

BACKGROUND: Localized scleroderma (LS) usually begins in childhood with a broad clinical spectrum and the diagnosis is often delayed.
OBJECTIVES: To investigate the diagnostic pathway in a large cohort of paediatric patients with LS, to identify the duration until correct diagnosis and to characterize clinical clues for early diagnosis.
METHODS: A retrospective case note review of 50 children with LS.
RESULTS: The median (range) age at disease onset was 5·2 (0·1-14·4) years and disease duration until diagnosis 11·1 (1·8-79) months. The patients were first seen by a general practitioner (or paediatrician) after 1·2 (0·2-48·7) months and in none of the cases was the condition recognized at presentation according to a parental questionnaire (no diagnosis in 44%, misdiagnosis of atopic eczema 20%, melanocytic naevus 8%, fungal infection 6%, bruise 4%, varicose vein 4%, bacterial infection 4% and others). The patients were referred to a local specialist (dermatologist in 72%) after a disease duration of 7·5 (1·0-70·9) months and in 64% the correct diagnosis was established. In 20% the diagnosis remained unknown, 8% were misdiagnosed as port-wine stains and others as atopic eczema and melanocytic naevus. The correct diagnosis was eventually identified by the referring dermatologists, the paediatric dermatologists at our hospital, external maxillofacial surgeons and a paediatrician in 29 (58%), 17 (34%), 3 (6%) and 1 (2%), respectively. Histology was performed in 15 (30%). The patients were commenced on appropriate treatment after a disease duration of 16·6 (1·8-113·4) months. The main clinical diagnostic clues were: Blaschko-linear distribution 76%, atrophic changes 68%, skin fibrosis 40% and loss of scalp hair or eyelashes 36%.
CONCLUSIONS: Physicians involved in the care of these children need to be aware of the characteristic clinical appearance of LS for early recognition and prompt initiation of treatment.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists 2011.

Entities:  

Mesh:

Year:  2011        PMID: 21895625     DOI: 10.1111/j.1365-2133.2011.10600.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  14 in total

Review 1.  Recent developments in diagnosis and assessment of morphea.

Authors:  Sarah Nouri; Heidi Jacobe
Journal:  Curr Rheumatol Rep       Date:  2013-02       Impact factor: 4.592

Review 2.  A Practical Approach to Juvenile Dermatomyositis and Juvenile Scleroderma.

Authors:  Liza J McCann; Clare E Pain
Journal:  Indian J Pediatr       Date:  2016-02       Impact factor: 1.967

3.  [Localized scleroderma (morphea) in childhood].

Authors:  L Weibel
Journal:  Hautarzt       Date:  2012-02       Impact factor: 0.751

Review 4.  Why, how, and when to use color Doppler ultrasound for improving precision in the diagnosis, assessment of severity and activity in morphea.

Authors:  Ximena Wortsman
Journal:  J Scleroderma Relat Disord       Date:  2018-09-24

Review 5.  Eyebrow and Eyelash Alopecia: A Clinical Review.

Authors:  Betty Nguyen; Jamie Katy Hu; Antonella Tosti
Journal:  Am J Clin Dermatol       Date:  2022-10-02       Impact factor: 6.233

Review 6.  Development of minimum standards of care for juvenile localized scleroderma.

Authors:  Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok
Journal:  Eur J Pediatr       Date:  2018-05-04       Impact factor: 3.183

7.  Risk factors for morphoea disease severity: a retrospective review of 114 paediatric patients.

Authors:  M S Pequet; K E Holland; S Zhao; B A Drolet; S S Galbraith; D H Siegel; Y E Chiu
Journal:  Br J Dermatol       Date:  2014-04       Impact factor: 9.302

Review 8.  Overview of Juvenile localized scleroderma and its management.

Authors:  Suzanne C Li; Rong-Jun Zheng
Journal:  World J Pediatr       Date:  2019-11-30       Impact factor: 2.764

Review 9.  [Morphea or localized scleroderma and extragenital lichen sclerosus].

Authors:  P Moinzadeh; A Kreuter; T Krieg; N Hunzelmann
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

10.  Delayed Treatment of Generalized Morphea due to Misdiagnosis as Vitiligo at an Oriental Medical Clinic.

Authors:  Howard Chu; Jae Won Lee; Young In Lee; Do Young Kim
Journal:  Ann Dermatol       Date:  2017-08-25       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.